camptothecin has been researched along with Vitreoretinopathy, Proliferative in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jurgensen, S; Nair, AR; Ramabhadran, R; Schliekelman, M; Thomas, MB; Wakefield, J | 1 |
Esser, P; Heimann, K; Hueber, A; Kociok, N; Weller, M; Winter, S | 1 |
2 other study(ies) available for camptothecin and Vitreoretinopathy, Proliferative
Article | Year |
---|---|
Inhibition of p53 by lentiviral mediated shRNA abrogates G1 arrest and apoptosis in retinal pigmented epithelial cell line.
Topics: Apoptosis; Camptothecin; Cell Cycle; Cell Line; Cell Proliferation; DNA Damage; Etoposide; G1 Phase; Gene Expression Regulation; Genes, p53; Genetic Vectors; Humans; Lentivirus; Pigment Epithelium of Eye; Promoter Regions, Genetic; RNA Interference; RNA, Messenger; Tumor Suppressor Protein p53; Vitreoretinopathy, Proliferative | 2005 |
The topoisomerase I inhibitors, camptothecin and beta-lapachone, induce apoptosis of human retinal pigment epithelial cells.
Topics: Apoptosis; Camptothecin; Cell Culture Techniques; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fas Ligand Protein; fas Receptor; Humans; Membrane Glycoproteins; Naphthoquinones; Pigment Epithelium of Eye; Topoisomerase I Inhibitors; Vitreoretinopathy, Proliferative | 1998 |